Stock listing

NASDAQ:LONA LeonaBio, Inc. Stock

Home listing (NASDAQ) of LeonaBio, Inc.

Follow LeonaBio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LONA

$2.02 USD -0.44 (-17.9%)

Close on Nov 20, 2026

Past year -55.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.91 – $2.49 USDNov 20, 2026
Volume
68,874 sharesNov 20, 2026
Market cap
$19.03M USDAt the close on Nov 20, 2026 · price × 9.42M shares outstanding
52-week range
$1.91 – $14.21 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$874,601 USDMedian day 47,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
LeonaBio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LONA · Home$2.02 USD-0.44 (-17.9%)68,874$2.36$2.485$1.91$2.46Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LONA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.02-0.44-17.9%$2.36$2.485$1.9168,874
$2.46-0.19-7.2%$2.71$2.93$2.3784,853
$2.65-0.11-4.0%$2.77$3.052$2.5144,498
$2.76-0.47-14.6%$3.17$3.32$2.7524,683
$3.23-0.24-6.9%$3.47$3.47$3.2058,410
$3.47-0.26-7.0%$3.75$3.95$3.4620,000
$3.73-0.15-3.9%$3.898$3.92$3.62325,500
$3.88-0.14-3.5%$4.055$4.055$3.6033,000
$4.02-0.45-10.1%$4.47$4.75$4.0186,100
$4.47+0.055+1.2%$4.44$4.80$4.2599,200
$4.415+0.075+1.7%$4.20$4.673$4.1350,000
$4.34-0.225-4.9%$4.55$4.83$4.2694,500
$4.565-0.205-4.3%$4.80$4.90$4.5374,300
$4.77+0.04+0.8%$4.69$4.90$4.6928,500
$4.73-0.21-4.3%$4.95$5.03$4.6326,700
$4.94+0.03+0.6%$4.89$5.14$4.7643,100
$4.91-0.05-1.0%$5.20$5.40$4.74161,800
$4.96+0.07+1.4%$4.94$5.10$4.76124,800
$4.89+0.13+2.7%$4.77$5.10$4.68118,700
$4.76-0.08-1.7%$4.80$5.00$4.5538,900
$4.84-0.13-2.6%$4.99$5.02$4.8333,800
$4.97-0.70-12.3%$5.59$5.671$4.6949,800
$5.67+0.40+7.6%$5.30$5.75$5.3011,800
$5.27+0.22+4.4%$5.11$5.46$4.8661,500
$5.05-0.15-2.9%$5.23$5.385$4.7741,000
$5.20-0.09-1.7%$5.30$5.43$5.1561,300
$5.29-0.10-1.9%$5.41$5.44$4.9135,200
$5.39-1.04-16.2%$6.33$6.33$5.25103,000
$6.43+0.265+4.3%$6.06$6.72$5.64957,400
$6.165+0.415+7.2%$5.82$6.397$5.57386,300
$5.750.000.0%$5.82$6.10$5.5666,700
$5.75-0.08-1.4%$5.78$6.07$5.515134,600
$5.83+0.08+1.4%$5.77$6.21$5.61178,100
$5.75+0.17+3.0%$5.63$5.88$5.25175,600
$5.58+0.76+15.8%$4.75$5.72$4.51295,600
$4.82+0.44+10.0%$4.44$4.90$4.18332,100
$4.38+0.81+22.7%$3.515$5.34$3.426,300,400
$3.57+0.06+1.7%$3.51$3.59$3.3140,300
$3.51+0.64+22.3%$2.80$3.75$2.57439,100
$2.87-0.38-11.7%$3.30$3.30$2.21948,900
$3.25-1.74-34.9%$5.19$5.595$3.12343,700
$4.99-0.90-15.3%$6.04$6.315$4.90151,000
$5.89-0.16-2.6%$6.35$6.35$5.6921,400
$6.05-0.28-4.4%$6.40$6.75$5.9534,900
$6.33-0.46-6.8%$6.715$6.76$6.2345,600
$6.79-0.16-2.3%$7.59$7.655$6.6152,300
$6.95+0.16+2.4%$6.86$6.95$6.7255,500
$6.79-0.45-6.2%$7.10$7.30$6.69651,300
$7.24-0.23-3.1%$6.90$7.47$6.9023,400
$7.47+0.55+7.9%$7.02$7.80$7.0223,300
$6.92+0.06+0.9%$6.75$7.64$6.7542,700
$6.86-0.18-2.6%$7.14$7.705$6.8142,300
$7.04-0.98-12.2%$7.90$8.195$7.0478,900
$8.02+0.46+6.1%$7.56$8.27$7.43259,300
$7.56-0.14-1.8%$7.925$7.925$7.43914,200
$7.70+0.03+0.4%$7.59$8.07$7.547,600
$7.67+0.08+1.1%$7.72$7.805$7.675,700
$7.59-0.33-4.2%$7.89$8.345$7.59154,400
$7.92-0.02-0.3%$8.025$8.40$7.9234,200
$7.94+0.05+0.6%$8.00$8.00$7.945,100
$7.89+0.08+1.0%$8.155$8.16$7.893,500
$7.81-0.20-2.5%$8.05$8.125$7.7624,400
$8.01+0.28+3.6%$7.76$8.21$7.70511,700
$7.73+0.045+0.6%$7.57$8.115$7.558,400
$7.685-0.015-0.2%$7.88$7.99$7.609,600
$7.70-0.13-1.7%$7.95$8.11$7.579,000

Splits

1 split · NASDAQ:LONA · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NASDAQ:LONA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All LeonaBio, Inc. news

LeonaBio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
10 in the last 12 months · 11 in all · newest Nov 16, 2026 · oldest 2025
Decks
10 decks · latest August 2026

Where LeonaBio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LONA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LONABOATSUnited StatesUSD
Frankfurt:6AIFrankfurtGermanyEUR

Valuation

Price/book 1.2× against a median of 1.7×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$12.82M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.04

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
LeonaBio, Inc. · NASDAQ:LONAUS$19.03M−US$12.82Mn/an/an/a1.2×n/a0.0×1.04
Aardvark Therapeutics, Inc. · NASDAQ:AARDUS$20.20M−US$39.58Mn/an/an/a0.3×n/a0.0×3.28
GenSight Biologics SA · EURONEXT:SIGHTUS$20.19MUS$32.44Mn/a29,573×n/an/an/an/an/a
TransCode Therapeutics, Inc. · NASDAQ:RNAZUS$20.07MUS$15.44Mn/an/an/a0.6×n/a0.0×1.03
Adicet Bio, Inc. · NASDAQ:ACETUS$20.03MUS$5.02Mn/an/an/a0.2×n/a0.1×2.02
IGC Pharma, Inc. · AMEX:IGCUS$19.60MUS$19.19Mn/an/an/a3.0×n/a0.0×1.09
Provectus Biopharmaceuticals, Inc. · OTC:PVCTUS$19.12MUS$18.94Mn/an/an/an/an/an/a-0.21
Cocrystal Pharma, Inc. · NASDAQ:COCPUS$18.30MUS$14.69Mn/a33.8×n/a6.8×n/a0.5×1.21
Syntara Limited · ASX:SNTUS$18.20MUS$9.23Mn/a2.0×n/a1.7×−129.8%0.0×n/a
Marker Therapeutics, Inc. · NASDAQ:MRKRUS$18.17MUS$9.13Mn/a4.9×n/a1.7×−461.1%0.0×1.49
Resverlogix Corp. · TSX:RVXUS$18.01MUS$95.55Mn/an/an/an/an/an/a0.26
Median of the othersUS$19.36MUS$15.06M19.3×1.7×−295.4%0.0×1.15

Forecasts

2 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
16.33 USD · Analysts' mean
EPS, year to Dec 2026
-3.88 · 2 analysts

Team and board

Officers

OfficerRole
Mark LittonPresident & CEO
Natalie HollesBoard Member | Chief Executive Officer
Robert RenningerChief Financial Officer
Mark WorthingtonGeneral Counsel, Chief Compliance Officer, & Corporate Secretary
Javier San MartinChief Medical Officer
Kevin ChurchChief Scientific Officer
Mark F. KubikChief Business Officer

Board

DirectorRole
Kelly RomanoChair
Barbara KosaczBoard Member
Fred CalloriBoard Member
Grant PickeringBoard Member
James JohnsonBoard Member
Joe EdelmanBoard Member
Mark LittonPresident & CEO
Michael A. PanzaraBoard Member
Natalie HollesBoard Member | Chief Executive Officer
Peter B. SilvermanBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−14.6%
Q2 2026Aug 14, 2026 · After close−3.2%
Q1 2026May 7, 2026 · After close+1.8%
Q4 2025Mar 27, 2026−4.3%
Q3 2025Nov 6, 2025 · After close−4.0%
Q2 2025Aug 7, 2025 · After close+6.0%
Q1 2025May 9, 2025 · After close+6.3%
Q4 2024Feb 27, 2025−6.4%
Q3 2024Nov 7, 2024 · After close−12.0%
Q2 2024Aug 1, 2024 · After close−1.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close+22.6%
Q4 2023Feb 22, 2024 · After close0.0%
Q3 2023Nov 9, 2023 · After close+6.5%
Q2 2023Aug 10, 2023 · After close−7.3%
Q1 2023May 11, 2023 · After close0.0%
Q4 2022Mar 23, 2023−1.6%
Q3 2022Nov 10, 2022 · After close+8.4%
Q2 2022Aug 15, 2022 · After close+1.5%
Q1 2022May 12, 2022 · After close+4.0%
Q4 2021Mar 24, 2022+13.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck36 slidesAugust 2026
Investor Presentation (March 2026)Investor deck41 slidesMar 26, 2026
Athira Pharma — Investor Presentation (December 2025)Investor deck42 slidesDec 18, 2025
Athira Pharma — Technical Presentation (September 2024)Technical15 slidesSep 3, 2024
Athira Pharma — Corporate Update (October 2022)Corporate update11 slidesOct 17, 2022
Athira Pharma — Technical Presentation (June 2022)Technical17 slidesJun 22, 2022
Athira Pharma — Proxy Contest (April 2022)Proxy contest36 slidesApr 26, 2022
Athira Pharma — Proxy Contest (April 2022)Proxy contest53 slidesApr 25, 2022
Athira Pharma — Investor Presentation (April 2022)Investor deck32 slidesApr 11, 2022
Athira Pharma — Investor Presentation (January 2021)Investor deck31 slidesJan 11, 2021

Open Decks

IPO

Went public as Athira Pharma, Inc. Priced at US$17.00 a share on Sep 17, 2020.

Price
US$17.00 a share
Shares offered
12,000,000 shares of common stock
Offering size
US$204 million
Underwriters' option
Up to 1,800,000 more shares
Listing
ATHA on the Nasdaq Global Select Market
Underwriters
Goldman Sachs & Co. LLC, Jefferies, Stifel, JMP Securities · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJul 24, 2020
Filed publiclyAug 26, 2020
Amended 3 timesNewest Sep 17, 2020
Shares registered with an exchangeSep 9, 2020
Declared effective by the SECSep 17, 2020
Final prospectus, with the priceSep 18, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Sep 18, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue00000
Cost of revenue68.1M479.0K2.00M
Gross profit-68.1M-479.0K-2.00M
Research and development17.5M70.7M93.8M61.5M42.8M13.3M3.79M3.59M
Selling, general and administrative16.7M26.1M33.3M32.6M21.2M6.71M1.66M1.42M
Operating income-102.3M-100.9M-125.5M-104.0M-64.0M-20.0M-5.45M-5.01M
Depreciation and amortization972.0K970.0K969.0K845.0K479.0K2.00K2.00K5.01M
EBITDA-101.3M-99.9M-124.5M-103.2M-63.5M-20.0M-5.45M0
Interest expense24.3M3.00K367.0K346.0K9.00K
Income before tax-105.6M-96.9M-117.4M-95.8M-55.0M-20.0M-5.16M-5.10M
Income tax0
Net income-105.6M-96.9M-117.7M-95.6M-54.9M-20.0M-5.16M-5.10M
Earnings per share, basic-24.70-25.19-3.09-2.53-1.49-1.67-1.45-1.56
Earnings per share, diluted-24.70-25.19-3.09-2.53-1.49-1.67-1.45

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents69.3M48.4M90.6M96.0M110.5M60.6M2.06M3.32M
Short-term investments19.1M2.84M56.8M104.4M143.2M124.1M1.50M
Receivables1.63M1.23M2.34M1.30M7.00K6.00K
Inventory-1.23M
Current assets89.5M54.8M154.7M207.5M260.8M192.3M2.16M4.90M
Property, plant and equipment1.47M2.44M3.39M4.05M3.76M2.65M
Total assets92.2M58.8M160.2M258.2M332.0M279.6M2.19M4.93M
Accounts payable4.59M319.0K129.0K2.50M567.0K1.16M421.0K121.0K
Current liabilities47.5M13.1M28.8M21.4M9.29M4.41M1.27M572.0K
Total debt803.0K1.22M1.58M1.91M1.92M1.00M1.55M722.0K
Total liabilities64.4M13.9M30.1M23.0M10.9M5.28M4.86M19.8M
Shareholders' equity27.8M44.8M130.2M235.1M321.1M274.3M-19.7M-14.9M
Shares outstanding9.34M3.90M38.2M37.9M37.4M32.5M3.64M3.26M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-45.7M-97.2M-100.8M-72.5M-43.1M-24.1M-3.71M-4.48M
Capital spending0-33.0K-304.0K-1.14M-1.57M-2.32M00
Free cash flow-45.7M-97.2M-101.1M-73.6M-44.7M-26.4M-3.71M-4.48M
Cash from investing-15.9M54.8M95.1M57.7M-4.08M-210.1M1.51M2.01M
Cash from financing82.5M194.0K493.0K654.0K97.1M292.8M946.0K1.46M
Change in cash20.8M-42.1M-5.17M-14.2M49.9M58.6M-1.26M-1.01M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 4, 2026Big-stake noticeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 28, 2026Big-stake noticeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 26, 2026Big-stake noticeSEC
8-K · Current reportSep 22, 2026Current reportSEC
3 · Initial statement of ownershipSep 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13D · Big-stake noticeAug 31, 2026Big-stake noticeSEC
8-K · Current reportAug 26, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 25, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 20, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMay 11, 2026Annual reportSEC
DEFA14A · Additional proxy materialMay 11, 2026Meeting noticeSEC
DEF 14A · Proxy statementMay 11, 2026Meeting noticeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 7, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 2, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 2, 2026Other filingsSEC
424B3 · ProspectusApr 1, 2026Offer documentSEC
424B3 · ProspectusApr 1, 2026Offer documentSEC
S-8 · Registration statement for employee plansApr 1, 2026Offer documentSEC
S-8 · Registration statement for employee plansApr 1, 2026Offer documentSEC
CORRESP · Letter to the SECMar 31, 2026Other filingsSEC
CORRESP · Letter to the SECMar 31, 2026Other filingsSEC
S-1/A · Registration statement, amendedMar 31, 2026Offer documentSEC
S-1/A · Registration statement, amendedMar 31, 2026Offer documentSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K/A · Current report, amendedMar 31, 2026Acquisition or disposalSEC
8-K · Current reportMar 26, 2026ResultsSEC
8-K · Current reportMar 19, 2026Management or board changeSEC
DEFR14AMar 10, 2026Meeting noticeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
DEF 14A · Proxy statementFeb 23, 2026Meeting noticeSEC
CORRESP · Letter to the SECFeb 20, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 11, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 11, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementFeb 4, 2026Meeting noticeSEC
S-3 · Registration statementJan 20, 2026Offer documentSEC
S-3 · Registration statementJan 20, 2026Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 16, 2026Big-stake noticeSEC
8-K · Current reportJan 9, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2026Big-stake noticeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 23, 2025Big-stake noticeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeDec 23, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 22, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 18, 2025Big-stake noticeSEC
8-K/A · Current report, amendedDec 18, 2025Material contractSEC
8-K · Current reportDec 18, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 10, 2025Big-stake noticeSEC
8-K · Current reportOct 3, 2025Current reportSEC
8-K · Current reportSep 11, 2025Current reportSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
8-K · Current reportJun 2, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportMay 9, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 16, 2025Big-stake noticeSEC
8-K · Current reportApr 16, 2025Current reportSEC
ARS · Annual report to shareholdersApr 14, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 14, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 14, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 4, 2025Meeting noticeSEC
4/A · Change in ownership, amendedMar 12, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G · Big-stake noticeNov 7, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 31, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveOct 29, 2024Other filingsSEC
UPLOAD · Letter from the SECOct 24, 2024Other filingsSEC
CORRESP · Letter to the SECOct 24, 2024Other filingsSEC
S-3 · Registration statementOct 21, 2024Offer documentSEC
8-K · Current reportOct 18, 2024Current reportSEC
8-K · Current reportOct 7, 2024Management or board changeSEC
4/A · Change in ownership, amendedOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 3, 2024Insider tradeSEC
8-K · Current reportSep 17, 2024Management or board changeSEC
144 · Notice of proposed saleSep 5, 2024Other filingsSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
8-K · Current reportSep 3, 2024Current reportSEC
10-Q/A · Quarterly report, amendedAug 9, 2024Quarterly reportSEC
10-Q · Quarterly reportAug 1, 2024Quarterly reportSEC
8-K · Current reportAug 1, 2024ResultsSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
8-K · Current reportMay 29, 2024Meeting outcomeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
8-K · Current reportMay 17, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
4 · Change in ownershipApr 16, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 9, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 9, 2024Meeting noticeSEC

This page holds 200 of 472 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from LeonaBio, Inc.’s releases

Common shares
9,421,663
Fully diluted
9,421,663

Fully diluted

LineShares
Common shares9,421,663

Share count over time

CountShares
Nov 22, 20269,421,663

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Perceptive Advisors LLC1.86M14.2%US$6.64MSep 30, 2026
Acorn Capital Advisors, LLC1.14M8.8%US$4.09MSep 30, 2026
ADAR1 Capital Management, LLC777K5.9%US$2.77MSep 30, 2026
Adage Capital Partners Gp, L.L.C.468K3.6%US$1.67MSep 30, 2026
TCG Crossover Management, LLC464K3.6%US$1.66MSep 30, 2026
NEA Management Company, LLC464K3.6%US$1.66MSep 30, 2026
Commodore Capital LP464K3.6%US$1.66MSep 30, 2026
Spruce Street Capital LP394K3.0%US$1.41MSep 30, 2026
Kalehua Capital Management LLC394K3.0%US$1.41MSep 30, 2026
Vanguard319K2.4%US$1.14MSep 30, 2026
All 47 holders
HolderSharesOf the companyValueAs of
Seven Fleet Capital Management LP158K1.2%US$565KSep 30, 2026
Simplify Asset Management Inc.149K1.1%US$533KSep 30, 2026
Propel Bio Management, LLC149K1.1%US$533KSep 30, 2026
Landscape Capital Management, L.L.C.99,1090.76%US$354KSep 30, 2026
Citadel86,2820.66%US$308KSep 30, 2026
Geode Capital85,3360.65%US$305KSep 30, 2026
BlackRock78,0590.60%US$279KSep 30, 2026
Renaissance Technologies56,9660.44%US$203KSep 30, 2026
Luminus Management LLC47,6560.36%US$170KSep 30, 2026
Nantahala Capital Management, LLC37,6610.29%US$134KSep 30, 2026
Bank of America32,5550.25%US$116KSep 30, 2026
Millennium28,6200.22%US$102KSep 30, 2026
Dimensional19,3810.15%US$69,190Sep 30, 2026
Jane Street18,0270.14%US$64,357Sep 30, 2026
State Street16,3370.12%US$58,323Sep 30, 2026
Northern Trust14,3940.11%US$51,387Sep 30, 2026
Two Sigma13,2760.10%US$47,395Sep 30, 2026
XTX Topco Ltd10,3570.08%US$36,974Sep 30, 2026
Acadian Asset Management LLC10,2300.08%US$36,000Sep 30, 2026
Laird Norton Wetherby Trust Company, LLC10,0880.08%US$36,014Sep 30, 2026
Scoggin Management LP10,0000.08%US$35,700Sep 30, 2026
Osaic Holdings, Inc.2,2000.02%US$7,721Sep 30, 2026
JPMorgan2,0120.02%US$7,062Sep 30, 2026
Tower Research Capital LLC (TRC)747<0.01%US$2,667Sep 30, 2026
Morgan Stanley578<0.01%US$2,063Sep 30, 2026
RBC250<0.01%US$1,000Sep 30, 2026
American Capital Advisory, LLC200<0.01%US$714Sep 30, 2026
Rothschild Investment LLC150<0.01%US$536Sep 30, 2026
McIlrath & Eck, LLC82<0.01%US$293Sep 30, 2026
US Bancorp \de\81<0.01%US$289Sep 30, 2026
UBS75<0.01%US$268Sep 30, 2026
Global Retirement Partners, LLC52<0.01%US$185Sep 30, 2026
Jones Financial Companies Lllp33<0.01%US$107Sep 30, 2026
BNP Paribas20<0.01%US$71Sep 30, 2026
SBI Securities Co., Ltd.12<0.01%US$43Sep 30, 2026
Barclays2<0.01%US$7Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%US$4Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund183K1.4%US$1.68MJun 30, 2026
Simplify Propel Opportunities ETF149K1.1%US$1.37MJun 30, 2026
Vanguard Extended Market Index Fund82,3900.63%US$757KJun 30, 2026
Fidelity Extended Market Index Fund35,9080.27%US$343KMay 31, 2026
iShares Micro-Cap ETF21,7440.17%US$200KJun 30, 2026
Fidelity Total Market Index Fund11,8460.09%US$113KMay 31, 2026
Fidelity Series Total Market Index Fund10,0080.08%US$95,476May 31, 2026
Fidelity Nasdaq Composite Index Fund6,2780.05%US$59,892May 31, 2026
Vanguard Institutional Total Stock Market Index Fund5,9880.05%US$55,030Jun 30, 2026
U.S. Micro Cap Portfolio3,7740.03%US$26,644Jul 31, 2026
All 20 holders
HolderSharesOf the companyValueAs of
Vanguard Balanced Index Fund3,5960.03%US$33,047Jun 30, 2026
Dimensional US Core Equity 1 ETF2,6140.02%US$18,455Jul 31, 2026
U.S. Vector Equity Portfolio1,5300.01%US$10,802Jul 31, 2026
1290 VT Micro Cap Portfolio1,4160.01%US$13,013Jun 30, 2026
U.S. Social Core Equity 2 Portfolio1,253<0.01%US$8,846Jul 31, 2026
U.S. Sustainability Core 1 Portfolio1,251<0.01%US$8,832Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF1,048<0.01%US$7,399Jul 31, 2026
U.S. Core Equity 1 Portfolio1,021<0.01%US$7,208Jul 31, 2026
Dimensional US Sustainability Core 1 ETF330<0.01%US$2,330Jul 31, 2026
Dimensional US Vector Equity ETF136<0.01%US$960Jul 31, 2026

Insider trades

TradeTradeSharesDate
Portman David J.
10% owner
Buy3,149,470Oct 26, 2026

Big stakes

StakeStakeSharesDateFiling
Sermonix Pharmaceuticals, Inc.25.10%3.15MOct 26, 2026Schedule 13D
Perceptive Advisors LLC19.99%1.89MOct 26, 2026Schedule 13D
Anders Hove12.10%1.49MAug 18, 2026Schedule 13G
ADAR1 Capital Management, LLC7.70%727KMar 31, 2026Schedule 13G
Great Point Partners LLC5.03%474KOct 28, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew Gengos
Other companies: Immuneering Corporation (Chief Financial Officer and Treasurer · Since at least Jul 16, 2026); Turn Therapeutics Inc. (Director · Since at least Oct 7, 2025); Terns Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Feb 24, 2025); Cyteir Therapeutics Inc (Chief Business Officer · Jun 17, 2021 – Feb 22, 2022 · Past); Synlogic Inc (Chief Operating Officer · Oct 9, 2017 – Mar 14, 2018 · Past)
CFO and Chief Business Officer · May 18, 2023 – Sep 3, 2024 · Past
Barbara Kosacz
Other companies: XOMA Royalty Corporation (Director · Since at least May 21, 2025); CERo Therapeutics Holdings, Inc. (Director · Oct 5, 2021 – Feb 14, 2024 · Past); Kronos Bio Inc (COO & General Counsel · Oct 8, 2020 – Jan 4, 2024 · Past)
Board Member · Since at least Mar 4, 2021
Fred Callori
Other companies: Astria Therapeutics Inc (Director · Since at least Jan 28, 2021); Landos Biopharma Inc (Director · Aug 27, 2021 – May 23, 2024 · Past)
Director · Since at least May 5, 2026
John M Fluke Jr
Other companies: Cellcyte Genetics Corporation (Interim PEO, Director · Jun 1, 2009 – Nov 8, 2011 · Past); PACCAR Inc. (Director · Jan 2, 2009 – Mar 5, 2015 · Past)
Director · Since at least Sep 17, 2020
Mark Litton
Other companies: Alpine Immune Sciences Inc (See Remarks · Aug 6, 2018 – Feb 6, 2019 · Past); Alder BioPharmaceuticals Inc (Chief Business Officer · May 7, 2014 – Jun 1, 2018 · Past)
President & CEO · Since at least Sep 17, 2020
Michael A. Panzara
Other companies: Immunic, Inc. (Chief Medical Officer · Since at least Apr 24, 2026); Wave Life Sciences Ltd. (See Remarks · Feb 1, 2021 – Jul 25, 2022 · Past)
Director · Since at least Mar 18, 2022
Martin Javier San
Other companies: Arrowhead Pharmaceuticals, Inc. (Chief Medical Officer · Nov 21, 2022 – Jan 4, 2024 · Past)
CHIEF MEDICAL OFFICER · Since at least Apr 15, 2024
Fred CalloriBoard Member · Since at least May 7, 2026
Grant PickeringBoard Member · Since at least Nov 5, 2026
James JohnsonBoard Member · Since at least Nov 5, 2026
All 21 people
PersonSeat
Javier San MartinChief Medical Officer · Since at least Jun 4, 2026
Joe EdelmanBoard Member · Since at least Nov 4, 2026
Kelly RomanoChair · Since at least Nov 5, 2026
Kevin ChurchChief Scientific Officer · Since at least Jun 30, 2025
Leen KawasPresident & CEO, Director · Sep 17, 2020 – Feb 18, 2021 · Past
Mark F. KubikChief Business Officer · Since at least Feb 3, 2026
Mark WorthingtonGeneral Counsel, Chief Compliance Officer, & Corporate Secretary · Since at least Jun 1, 2021
Natalie HollesBoard Member | Chief Executive Officer · Since at least May 7, 2026
Peter B. SilvermanBoard Member · Since at least May 5, 2026
Rachel LeningtonCOO and CDO · Jan 4, 2024 – Sep 3, 2024 · Past
Robert RenningerChief Financial Officer · Since at least Oct 1, 2024

Open People

Log in to ask 6ix AI your own questions about LeonaBio, Inc.